A citation-based method for searching scientific literature

K A Frey, R A Koeppe, M R Kilbourn, T M Vander Borght, R L Albin, S Gilman, D E Kuhl. Ann Neurol 1996
Times Cited: 239







List of co-cited articles
1023 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
Nicolaas I Bohnen, Roger L Albin, Robert A Koeppe, Kristine A Wernette, Michael R Kilbourn, Satoshi Minoshima, Kirk A Frey. J Cereb Blood Flow Metab 2006
170
32

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
C S Lee, A Samii, V Sossi, T J Ruth, M Schulzer, J E Holden, J Wudel, P K Pal, R de la Fuente-Fernandez, D B Calne,[...]. Ann Neurol 2000
366
20

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A J Hughes, S E Daniel, L Kilford, A J Lees. J Neurol Neurosurg Psychiatry 1992
20

In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
Nobuyuki Okamura, Victor L Villemagne, John Drago, Svetlana Pejoska, Rajinder K Dhamija, Rachel S Mulligan, Julia R Ellis, Uwe Ackermann, Graeme O'Keefe, Gareth Jones,[...]. J Nucl Med 2010
84
21



Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Mei-Ping Kung, Catherine Hou, Rajesh Goswami, Datta E Ponde, Michael R Kilbourn, Hank F Kung. Nucl Med Biol 2007
56
26

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
H Bernheimer, W Birkmayer, O Hornykiewicz, K Jellinger, F Seitelberger. J Neurol Sci 1973
13

Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Rajesh Goswami, Datta E Ponde, Mei-Ping Kung, Catherine Hou, Mike R Kilbourn, Hank F Kung. Nucl Med Biol 2006
56
23

Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.
J M Wilson, A I Levey, A Rajput, L Ang, M Guttman, K Shannak, H B Niznik, O Hornykiewicz, C Pifl, S J Kish. Neurology 1996
169
11

Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease.
W R Wayne Martin, Marguerite Wieler, A Jon Stoessl, Michael Schulzer. Ann Neurol 2008
46
23

Parkinsonism: onset, progression and mortality.
M M Hoehn, M D Yahr. Neurology 1967
11

Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
Kun-Ju Lin, Yi-Hsin Weng, Shiaw-Pyng Wey, Ing-Tsung Hsiao, Chin-Song Lu, Daniel Skovronsky, Hsiu-Ping Chang, Mei-Ping Kung, Tzu-Chen Yen. J Nucl Med 2010
39
28

Staging of brain pathology related to sporadic Parkinson's disease.
Heiko Braak, Kelly Del Tredici, Udo Rüb, Rob A I de Vos, Ernst N H Jansen Steur, Eva Braak. Neurobiol Aging 2003
10

Distribution volume ratios without blood sampling from graphical analysis of PET data.
J Logan, J S Fowler, N D Volkow, G J Wang, Y S Ding, D L Alexoff. J Cereb Blood Flow Metab 1996
10

The role of radiotracer imaging in Parkinson disease.
B Ravina, D Eidelberg, J E Ahlskog, R L Albin, D J Brooks, M Carbon, V Dhawan, A Feigin, S Fahn, M Guttman,[...]. Neurology 2005
232
10

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E Klunk, Henry Engler, Agneta Nordberg, Yanming Wang, Gunnar Blomqvist, Daniel P Holt, Mats Bergström, Irina Savitcheva, Guo-feng Huang, Sergio Estrada,[...]. Ann Neurol 2004
10

Imaging the vesicular monoamine transporter.
K A Frey, R A Koeppe, M R Kilbourn. Adv Neurol 2001
63
14

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
J S Rakshi, T Uema, K Ito, D L Bailey, P K Morrish, J Ashburner, A Dagher, I H Jenkins, K J Friston, D J Brooks. Brain 1999
210
9

[3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity.
T M Vander Borght, A A Sima, M R Kilbourn, T J Desmond, D E Kuhl, K A Frey. Neuroscience 1995
83
10

Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
Michael R Kilbourn, Brian Hockley, Lihsueh Lee, Catherine Hou, Rajesh Goswami, Datta E Ponde, Mei-Ping Kung, Hank F Kung. Nucl Med Biol 2007
33
27

Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Isabelle Boileau, Pablo Rusjan, Sylvain Houle, Diana Wilkins, Junchao Tong, Peter Selby, Mark Guttman, Jean A Saint-Cyr, Alan A Wilson, Stephen J Kish. J Neurosci 2008
62
14

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.
G W Miller, J D Erickson, J T Perez, S N Penland, D C Mash, D B Rye, A I Levey. Exp Neurol 1999
138
8

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
P K Morrish, J S Rakshi, D L Bailey, G V Sawle, D J Brooks. J Neurol Neurosurg Psychiatry 1998
368
8

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
D J Brooks, V Ibanez, G V Sawle, N Quinn, A J Lees, C J Mathias, R Bannister, C D Marsden, R S Frackowiak. Ann Neurol 1990
499
8

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.
Alexander Gerhard, Nicola Pavese, Gary Hotton, Federico Turkheimer, Meltem Es, Alexander Hammers, Karla Eggert, Wolfgang Oertel, Richard B Banati, David J Brooks. Neurobiol Dis 2006
655
8

Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.
G L Chan, J E Holden, A J Stoessl, A Samii, D J Doudet, T Dobko, K S Morrison, M Adam, M Schulzer, D B Calne,[...]. J Nucl Med 1999
43
18



VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.
Ming-Kai Chen, Hiroto Kuwabara, Yun Zhou, Robert J Adams, James R Brasić, Jennifer L McGlothan, Tatyana Verina, Neal C Burton, Mohab Alexander, Anil Kumar,[...]. J Neurochem 2008
80
10




[3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain.
D Scherman, R Raisman, A Ploska, Y Agid. J Neurochem 1988
78
10



Alpha-synuclein in Lewy bodies.
M G Spillantini, M L Schmidt, V M Lee, J Q Trojanowski, R Jakes, M Goedert. Nature 1997
8


Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.
Vesna Sossi, Raúl de La Fuente-Fernández, James E Holden, Doris J Doudet, Jess McKenzie, A J Stoessl, T J Ruth. J Cereb Blood Flow Metab 2002
89
7

A reversible tracer analysis approach to the study of effective dopamine turnover.
V Sossi, D J Doudet, J E Holden. J Cereb Blood Flow Metab 2001
52
13

Decreased dopamine transporters with age in health human subjects.
N D Volkow, J S Fowler, G J Wang, J Logan, D Schlyer, R MacGregor, R Hitzemann, A P Wolf. Ann Neurol 1994
145
7

Dopamine transporter imaging with fluorine-18-FPCIT and PET.
K Kazumata, V Dhawan, T Chaly, A Antonini, C Margouleff, A Belakhlef, J Neumeyer, D Eidelberg. J Nucl Med 1998
118
7


Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
J J Frost, A J Rosier, S G Reich, J S Smith, M D Ehlers, S H Snyder, H T Ravert, R F Dannals. Ann Neurol 1993
297
7

VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
Raúl De La Fuente-Fernández, Sarah Furtado, Mark Guttman, Yoshiaki Furukawa, Chong S Lee, Donald B Calne, Thomas J Ruth, A Jon Stoessl. Synapse 2003
46
15

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.
T Vander Borght, M Kilbourn, T Desmond, D Kuhl, K Frey. Eur J Pharmacol 1995
170
7

Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
R A Koeppe, K A Frey, T M Vander Borght, A Karlamangla, D M Jewett, L C Lee, M R Kilbourn, D E Kuhl. J Cereb Blood Flow Metab 1996
74
9

Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Ing-Tsung Hsiao, Yi-Hsin Weng, Chia-Ju Hsieh, Wey-Yil Lin, Shiaw-Pyng Wey, Mei-Ping Kung, Tzu-Chen Yen, Chin-Song Lu, Kun-Ju Lin. JAMA Neurol 2014
60
11

Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.
Vesna Sossi, Raúl de la Fuente-Fernández, James E Holden, Michael Schulzer, Thomas J Ruth, Jon Stoessl. J Cereb Blood Flow Metab 2004
66
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.